Lynda Wyld is Professor of Surgical Oncology at the University of Sheffield and a Consultant Oncoplastic Surgeon at Doncaster and Bassetlaw Teaching Hospitals. She is the Past President of the British Association of Surgical Oncology (BASO) and Past Chair of the European Society of Surgical Oncology (ESSO) Education Committee and is a Trustee of the Association of Breast Surgery (ABS).

Ramsey Cutress is Professor of Breast Surgery at University of Southampton and a Consultant Surgeon at University Hospital Southampton. He is Chair of the Association of Breast Surgery (ABS) Academic and Research Committee, Course Director for the ABS Advanced Skills in Breast Disease Management course, Head of the School for Clinical Academic Training at the Wessex Deanery and breast disease subspecialty editor for the Annals of the Royal College of Surgeons of England, demonstrating his interests in research and teaching.

Jenna Morgan Jenna is an NIHR Advanced Fellow Breast Surgery at the University of Sheffield and a Consultant Oncoplastic Surgeon at the Jasmine Breast Unit in Doncaster, UK. She is Past Chair of the Mammary Fold Academic Committee of the ABS. She is a clinical academic with an interest in mixed methods research, geriatric oncology and the psychology or ageing in healthcare settings.

Section One: Epidemiology

1. Type and timing of menopausal hormone therapy and breast cancer risk: individual participant meta-analysis of the worldwide epidemiological evidence

Collaborative Group on Hormonal Factors in Breast Cancer

2. Moderate Alcohol Intake and Cancer Incidence in Women

Allen N, Beral V, Cassabone D, Kan SW, Reeves GK, Brown A, Green J on behalf of the Million Women Study Collaborators

Section Two: Screening and Prevention

3. 3. Tamoxifen for Prevention of Breast Cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study (NASBP P-1)

Fisher B, Costantino J, Wickerman D, et al

4. 4. The Swedish two county trial of mammographic screening for breast cancer: recent results and calculation of benefit.

Tabar L, Fagerberg G, Duffy SW, et al

5. 5. The benefits and harms of breast cancer screening: an independent review

Marmot MG, Altman DG, Cameron DA, Dewar JA, Thompson SG, Wilcox M.

Section Three: Diagnostic Imaging

6. 6. Diagnostic Performance of Digital versus Film Mammography for Breast-Cancer Screening (DMIST)

Pisano ED, Gatsonis C, Hendrick E, Yaffe M, Baum JK, Acharyya S, Conant EF, Fajardo LL, Bassett L, D'Orsi C, Jong R, Rebner M

7. Screening with magnetic resonance imaging and mammography of a UK population at high familial risk of breast cancer: a prospective multicentre cohort study (MARIBS)

Leach MO, Boggis CRM, Dixon AK, Easton DF, et al

8. Comparative effectiveness of MRI in breast cancer (COMICE) trial: a randomised controlled trial

Turnbull L, Brown S, Harvey I, Olivier C, Drew P, Napp V, Hanby A, Brown J

Section Four: Surgery: Mastectomy versus conservation

9. 9. Twenty-year follow-up of a randomized trial comparing total mastectomy, lumpectomy, and lumpectomy plus irradiation for the treatment of invasive breast cancer

Fisher B, Anderson S, Bryant J, Margolese RG, Deutsch M, Fisher ER, Jeong JH, Wolmark N

10. The Association of Surgical Margins and Local Recurrence in Women with Early-Stage Invasive Breast Cancer Treated with Breast Conserving Therapy: A Meta-Analysis

Houssami N, Macaskill P, Marinovich ML, Morrow M

11. Ten year survival after breast-conserving surgery plus radiotherapy compared with mastectomy in early breast cancer in the Netherlands: a population-based study

van Maaren MC, de Munck L, de Back GH, Jobsen J, van Dalen T, Poortmans P, Strobbe LC, Siesling S.

Section Five: De-escalation of Axillary Surgery

12. 12. Twenty-five-year follow-up of a randomized trial comparing radical mastectomy, total mastectomy, and total mastectomy followed by irradiation.

Fisher B, Jeong JH, Anderson S, Bryant J, Fisher ER, Wolmark N

13.13. Effect of Axillary Dissection vs No Axillary Dissection on 10-Year Overall Survival Among Women with Invasive Breast Cancer and Sentinel Node Metastasis: The ACOSOG Z0011 (Alliance) Randomized Clinical Trial.

Giuliano AE, Ballman KV, McCall L, et al.

14. 14. Radiotherapy or surgery of the axilla after a positive sentinel node in breast cancer (EORTC 10981-22023 AMAROS): a randomised, multicentre, open-label, phase 3 non-inferiority trial.

Donker M, van Tienhoven G, Straver ME, et al

1515. Sentinel Lymph Node Surgery After Neoadjuvant Chemotherapy in Patients With Node-Positive Breast Cancer: The ACOSOG Z1071 (Alliance) Clinical Trial

Boughey JC, Suman VJ, Mittendorf EA, et al.

Section Six: Oncoplastic Breast Surgery / Breast Reconstruction

16. 16. Planning and use of therapeutic mammaplasty-Nottingham approach

S J McCulley and R D Macmillan

17.17. Oncoplastic breast¿conserving surgery for women with primary breast cancer

Nanda A, Hu J, Hodgkinson S, Ali S, Rainsbury R, Roy PG.

18.18. Short-term safety outcomes of mastectomy and immediate implant-based breast reconstruction with and without mesh (iBRA): a multicentre, prospective cohort study

Potter et al

19.19. Improving Breast Cancer Surgery: A Classification and Quadrant per Quadrant Atlas for Oncoplastic Surgery

Clough KB, Kaufman GJ, Nos C, Buccimazza I, Sarfati IM

Section Seven: Breast cancer genomics and prognostic tools

20.20. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications

Therese Sørlie, Charles M. Perou, Robert Tibshirani, Turid Aas, Stephanie Geisler, Hilde Johnsen, et al.

21.21. Comprehensive molecular portraits of human breast tumours

The cancer Genome Atlas Network

2222. 70-Gene Signature as an Aid to Treatment Decisions in Early-Stage Breast Cancer

Fatima Cardoso, Laura J. van't Veer, Jan Bogaerts, et al for the MINDACT investigators

23. 23. 21-Gene Assay to Inform Chemotherapy Benefit in Node-Positive Breast Cancer (RxPonder)

K. Kalinsky, W.E. Barlow, J.R. Gralow, et al

24.24. PREDICT: a new UK prognostic model that predicts survival following surgery for invasive breast cancer

Gordon C Wishart, Elizabeth M Azzato, David C Greenberg, Jem Rashbass, Olive Kearins, Gill Lawrence, Carlos Caldas, and Paul DP Pharoah

Section Eight: Ductal Carcinoma In Situ

25 25. Genomic analysis defines clonal relationships of ductal carcinoma in situ and recurrent invasive breast cancer.

Esther H. Lips, Tapsi Kumar, Anargyros Megalios, Lindy L. Visser, Michael Sheinman, Angelo Fortunato, et al

26.26. Pathological features of 11,337 patients with primary ductal carcinoma in situ (DCIS) and subsequent events: results from the Sloane Project

Shaaban AM, Hilton B, Clements K, Provenzano E, Cheung S, Wallis MG, Sawyer ES, Thomas JS, Hanby AM, Pinder SE, Thompson AM

27. 27. Effect of tamoxifen and radiotherapy in women with locally excised ductal carcinoma in situ: long-term results from the UK/ANZ DCIS trial.

Cuzick J, Sestak I, Pinder SE, Ellis IO, Forsyth S, Bundred NJ, Forbes JF, Bishop H, Fentiman IS, George WD

28. 28. A prognostic index for ductal carcinoma in situ of the breast.

Silverstein MJ, Poller D, Craig PH, et al

Section Nine: Adjuvant Chemotherapy

29. 29. Comparisons between different polychemotherapy regimens for early breast cancer: meta-analyses of long-term outcome among 100,000 women in 123 randomised trials

Peto, R., Davies, C., Godwin, J., Gray, R., Pan, H. C., Clarke, M., Cutter, D., Darby, S., McGale, P., Taylor, C., Wang, Y. C., Bergh, J., Di Leo, A., Albain, K., Swain, S., Piccart, M., & Pritchard, K

30. 30. Adjuvant Capecitabine for Breast Cancer after Preoperative Chemotherapy. CREATE-X

N Masuda, Soo-Jung Lee, S Ohtani, Y-H Im, E-S Lee, I Yokota, K Kuroi, S-A Im, B-W Park, S-B Kim, Y Yanagita, and S Ohno et al

Section Ten: Adjuvant Endocrine Therapy

31. 31. Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials

Early Breast Cancer Trialists' Collaborative Group (EBCTCG)

32.32. Long term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor - positive breast cancer: ATLAS, a randomised trial

C Davies et al

33. 33. Tailoring Adjuvant Endocrine Therapy for Premenopausal Breast Cancer

Prudence A Francis et al

34.34. Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trial

ATAC Trialist's Group

Section Eleven: Immunotherapy / Systemic Therapy

35. 35. 11 years' follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive early breast cancer: final analysis of the HERceptin Adjuvant (HERA) trial

Cameron D, Piccart-Gebhart MJ, Gelber RD, Procter M, Goldhirsch A, de Azambuja E, et al & Herceptin Adjuvant (HERA) Trial Study Team

36.36. Adjuvant Olaparib for Patients with BRCA1- or BRCA2-Mutated Breast Cancer

Tutt ANJ, Garber JE, Kaufman B, et al

37.37. Pembrolizumab for Early Triple-Negative Breast Cancer

Schmid, P., et al

38.38. Trastuzumab Emtansine for Residual Invasive HER2-Positive Breast Cancer

von Minckwitz, Huang, Mano, et al. for the KATHERINE Investigators

Section Twelve: Adjuvant Radiotherapy

39.39. Breast-conserving surgery with or without irradiation in early breast cancer (PRIME II).

Ian H Kunkler et al

40.40. Effect of radiotherapy after breast-conserving surgery on 10-year recurrence and 15-year breast cancer death: meta-analysis of individual patient data for 10 801 women in 17 randomised trials

Early Breast Cancer Trialists' Collaborative Group (EBCTCG)

41.41. Whole-breast irradiation with or without a boost for patients treated with breast-conserving surgery for early breast cancer: 20-year follow-up of a randomised phase 3 trial.

H Bartelink et al

42.42. Effect of radiotherapy after mastectomy and axillary surgery on 10-year recurrence and 20-year breast cancer mortality: meta-analysis of individual patient data for 8135 women in 22 randomised trials.

Early Breast Cancer Trialists' Collaborative Group (EBCTCG)

43.43. Hypofractionated breast radiotherapy for 1 week versus 3 weeks (FAST-Forward): 5-year efficacy and late normal tissue effects; results from a multicentre, non-inferiority, randomised, phase 3 trial.

Brunt AM, et al

Section Thirteen:...